title: Gentamicin release from modified acrylic bone cements with lactose and hydroxypropylmethylcellulose.
abstract: Modified polymethylmethacrylate (PMMA) bone cements formulations were prepared by including different proportions of gentamicin and release modulators such as lactose or hydroxypropylmethylcellulose (HPMC). Surface aspect, gentamicin release and porosity of these modified formulations were studied by means of scanning electron microscopy (SEM), a specially designed system for the dissolution studies of the bone cements, and mercury intrusion porosimetry. Lactose modified cements presented an irregular surface with numerous hollows and voids due to the lactose dissolution. HPMC cements presented a characteristic laminated and flaky surface. The drug release of lactose formulations was up to four-fold greater (13%) than the commercial bone cement CMW1 Gentamicin one (3%). The amount of gentamicin eluted at the first withdrawn sample ranged from 30% to 60% of total gentamicin released over the assay. Gentamicin release from lactose formulations increased as lactose percentage was increased which agree with the porosity results. Nevertheless, the use of release modulator HPMC increased porosity, but did not produce an increase in the gentamicin release. HPMC dissolution creates a surrounding sticky and viscous medium similar to a gel that makes the gentamicin release from the cement matrix difficult.
authors.affiliation: Department of Pharmacy and Pharmaceutical Technology, School of Pharmacy, Complutense University, Madrid 28040, Spain.
authors.forename: M R
authors.initials: MR
authors.lastname: Virto
authors.forename: P
authors.initials: P
authors.lastname: Frutos
authors.forename: Susana
authors.initials: S
authors.lastname: Torrado
authors.forename: G
authors.initials: G
authors.lastname: Frutos
mesh_terms: D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000493:pharmacokinetics; D001843:Bone Cements; D003692:Delayed-Action Preparations; D004343:Drug Implants; D005839:Gentamicins / Q000008:administration & dosage* / Q000493:pharmacokinetics; D006801:Humans; D066298:In Vitro Techniques; D007785:Lactose / Q000031:analogs & derivatives*; D008422:Materials Testing; D008747:Methylcellulose / Q000031:analogs & derivatives*; D008855:Microscopy, Electron, Scanning; D010019:Osteomyelitis / Q000188:drug therapy; D010078:Oxazines; D019904:Polymethyl Methacrylate
chemical_list: D000900:Anti-Bacterial Agents; D001843:Bone Cements; D003692:Delayed-Action Preparations; D004343:Drug Implants; D005839:Gentamicins; D010078:Oxazines; D008747:Methylcellulose; D019904:Polymethyl Methacrylate; C071191:MK 458; D007785:Lactose